Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Abstract: Systems and methods include a database of a financial institution that maintains a respective status of a plurality of mobile automated teller machines (ATMs), the status of each of the plurality of mobile ATMs indicating the location of the respective mobile ATM and the amount of cash available for withdrawal from the mobile ATM, a communication interface that receives a request for a mobile ATM from a user device via a network, the request including user device location data, a location processor that compares the user device location data to location data associated with the plurality of mobile ATMs, and determines a first mobile ATM from the plurality of mobile ATMs that is closest to the user device based on the user device location data, and a transaction processor of a backend system of the financial institution that processes a transaction based on received confirmation.

Abstract: Systems and methods include a database of a financial institution that maintains a respective status of a plurality of mobile automated teller machines (ATMs), the status of each of the plurality of mobile ATMs indicating the location of the respective mobile ATM and the amount of cash available for withdrawal from the mobile ATM, a communication interface that receives a request for a mobile ATM from a user device via a network, the request including user device location data, a location processor that compares the user device location data to location data associated with the plurality of mobile ATMs, and determines a first mobile ATM from the plurality of mobile ATMs that is closest to the user device based on the user device location data, and a transaction processor of a backend system of the financial institution that processes a transaction based on received confirmation.

Abstract: Systems and methods include a database of a financial institution that maintains a respective status of a plurality of mobile automated teller machines (ATMs), the status of each of the plurality of mobile ATMs indicating the location of the respective mobile ATM and the amount of cash available for withdrawal from the mobile ATM, a communication interface that receives a request for a mobile ATM from a user device via a network, the request including user device location data, a location processor that compares the user device location data to location data associated with the plurality of mobile ATMs, and determines a first mobile ATM from the plurality of mobile ATMs that is closest to the user device based on the user device location data, and a transaction processor of a backend system of the financial institution that processes a transaction based on received confirmation.

Abstract: The disclosed technology includes a plurality of driverless mobile automated teller machines (ATMs), a communication interface configured to receive, from a user device, a request for a driverless mobile ATM to complete facilitate a transaction, a location processor configured to determine a first driverless mobile ATM of the plurality of driverless mobile ATMs that is closest to the user device, wherein the communication interface is further configured to transmit, to the first driverless mobile ATM, an alert including the request such that the first driverless mobile ATM can provide cash to a user associated with the user device or can receive cash or a check from the user, and a transaction processor of a backend system of the financial institution configured to process the transaction.

Abstract: Systems and methods include a database of a financial institution that maintains a respective status of a plurality of driverless mobile automated teller machines (ATMs), the status of each of the plurality of driverless mobile ATMs indicating the location of the respective driverless mobile ATM and the amount of cash available for withdrawal from the driverless mobile ATM, a communication interface that receives a request for a driverless mobile ATM from a user device via a network, the request including user device location data, a location processor that compares the user device location data to location data associated with the plurality of mobile ATMs, and determines a first mobile ATM from the plurality of driverless mobile ATMs that is closest to the user device based on the user device location data, wherein the communication interface transmits a first alert that includes the request to the first driverless mobile ATM via a network, receives a response from the driverless mobile ATM via the network,

Abstract: The present invention is directed to novel 4-methylpyridopyrimidinone compounds of Formula (I), and to salts thereof, their synthesis, and their use as inhibitors of phosphoinositide 3-kinase alpha (PI3-K?).

Abstract: Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

Abstract: The present invention relates to novel polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a hyperproliferative disorder or a mammalian disease condition mediated by protein kinase activity.

Abstract: The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.

Abstract: The invention relates to methods of inhibiting SARS-related coronavirus viral replication activity comprising contacting a SARS-related coronavirus protease with a therapeutically effective amount of a SARS 3C like protease inhibitor, and compositions comprising the same.